» Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration
Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the first patient has been dosed in the VIEW 2 trial, a second Phase 3 clinical study in a development program…